Morgan Stanley’s ProShares Ultra CRCL CRCA Stock Holding History

Morgan Stanley’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,000	Closed	-$537K	–	8690
2026 Q1	$537K	Buy	13,000 +11,760	+948%	+$488K	﹤0.01%	5452
2025 Q4	$50.1K	Buy	1,240 +540	+77%	+$46.3K	﹤0.01%	6440
2025 Q3	$102K	Buy	+700	New	+$113K	﹤0.01%	6140

Other funds holding CRCA

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Morgan Stanley's CRCA Position: Q2 2026 in Review

Morgan Stanley sold out of ProShares Ultra CRCL (CRCA) in Q2 2026, closing a stake of 13,000 shares — an estimated $537K sold.

Morgan Stanley first reported a position in CRCA in Q3 2025 and held it in 3 quarters. The position peaked at $537K in Q1 2026. 7 funds tracked by Wall St. Rank hold CRCA as of Q2 2026.

Morgan Stanley reported no remaining ProShares Ultra CRCL position as of Q2 2026 after selling out during the quarter.
Morgan Stanley sold 13,000 ProShares Ultra CRCL shares in Q2 2026, an estimated $537K.
Morgan Stanley first reported a position in ProShares Ultra CRCL in Q3 2025 and held it in 3 quarters.
Morgan Stanley's ProShares Ultra CRCL position peaked at $537K in Q1 2026.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.